Name: Invex Therapeutics (IXC) Short Position History
Creator: Shorted
License: https://creativecommons.org/licenses/by/4.0/

IXC

Pharmaceuticals, Biotechnology & Life Sciences

Invex Therapeutics

Short interest: 0.00%; 0.00 pp 30d; as of 1 Oct 2025
Reported shorts: 3.5K
Shares on issue: 75.154M

Price & short interest

Toggle series, zoom, and compare · ASIC daily, T+4

About Invex Therapeutics

Invex Therapeutics is a biopharmaceutical company focused on developing treatments for neurological conditions caused by raised intracranial pressure (ICP). The company is repurposing the drug Exenatide, trademarked as Presendin™, to address this significant unmet medical need. Invex aims to leverage its research and development expertise to provide efficacious solutions for conditions like idiopathic intracranial hypertension and traumatic brain injury.

Company profile →

Invex Therapeutics (ASX:IXC) has 0.00% of its shares on issue reported as short positions as of 1 Oct 2025, or about 3,544 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 1.12% in May 2020. IXC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.

Short interest

History & FAQ →

Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.

Strategy fit

How each stock picker strategy reads IXC today

Zanger BreakoutWatchScore 22rank 1129 of 1942
CAN SLIMWatchScore 15rank 861 of 1541
Minervini Trend TemplateWatchScore 28rank 621 of 1716
Crowded-Short BreakoutWatchScore 11rank 836 of 1502
Quality compoundersWatchScore 10rank 1354 of 1669

Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →

IXC fundamentals

In the year to 30 Jun 2026, Invex Therapeutics (ASX:IXC) recorded revenue of A$175.2K and a net loss after tax of A$1.4M. A year earlier it recorded revenue of A$461.5K and a net loss after tax of A$476.9K. Year-on-year growth: revenue −62.0% (FY). Net margin −772.1% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.

Full statements, ratios and filings are on the Financials tab. Not financial advice.

Full financials →